

# Biovail Corporation announced that the Company will participate at the UBS Global Specialty Pharmaceuticals Conference

May 29, 2009

TORONTO--(BUSINESS WIRE)--May. 29, 2009-- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that the Company will participate at the UBS Global Specialty Pharmaceuticals Conference in London, UK and the Goldman Sachs Annual Healthcare Conference in New York, NY.

Biovail's UBS conference presentation is scheduled for Tuesday, June 2, 2009 at 1:30 PM GMT (8:30 AM EDT). The Goldman Sachs conference presentation is scheduled for Thursday, June 11, 2009 at 11:00 AM EDT. A live and archived Webcast will be available on the Investor Relations page of Biovail's Web site at

[www.biovail.com](http://www.biovail.com)

## About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company's Web site at

[www.biovail.com](http://www.biovail.com)

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to [ir@biovail.com](mailto:ir@biovail.com)

Source: Biovail Corporation

## Biovail Corporation

Nelson F. Isabel, (905) 286-3000

Vice President, Investor Relations & Corporate Communications

## Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)



[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

## Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

CALIFORNIA RESIDENTS: DO NOT SELL MY  
PERSONAL INFORMATION

